Navigation Links
BioMS Medical to present at Rodman and Renshaw Annual Healthcare Conference
Date:11/5/2008

Toronto Stock Exchange Symbol: MS

EDMONTON, Nov. 5 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Mr. Kevin Giese, President and CEO, will present at the Rodman and Renshaw 10th Annual Healthcare Conference in New York.

WHEN: Monday November 10th at 12:00pm (Eastern Time)

WHERE: New York Palace Hotel, New York.

About BioMS Medical Corp.

-------------------------

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, dirucotide (MBP8298), is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. It additionally is being evaluated for relapsing remitting MS patients in a Phase II trial in Europe entitled MINDSET-01. In December 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Company exclusive worldwide rights to dirucotide (MBP8298), in exchange for an $87 million upfront payment, milestone payments and escalating royalties on sales. For further information please visit our website at http://www.biomsmedical.com.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, th
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
2. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
3. BioMS Medical announces receipt of milestone payment from Eli Lilly and Company
4. BioMS Medical to present at Sachs Associates Biotech in Europe Forum
5. BioMS Medical to present at UBS Global Life Sciences Conference
6. BioMS Medicals lead drug, dirucotide (MBP8298) for the treatment of multiple sclerosis, receives fast track designation from FDA
7. BioMS Medical announces its intention to renew a normal course issuer bid
8. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
9. BioMS Medical Announces Second Quarter 2008 Results
10. BioMS Medical completes patient recruitment in phase III U.S. multiple sclerosis trial
11. BioMS Medical to present at BMO Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... Diasome Pharmaceuticals, Inc. ( http://www.diasome.com ) has received ... States patent has recently been allowed for the Company’s ... “Lipid Construct for Delivery of Insulin to a Mammal,” ... the use of Diasome’s proprietary Hepatocyte Directed Vesicles (“HDV”) ... effectively reach the liver’s metabolic cells, called hepatocytes. , ...
(Date:3/30/2015)... PMG Research, Benchmark Research, and Miami ... of VaxCorps, a network of highly experienced, geographically ... of vaccine trials in healthy adult, elderly, and ... conducted over 500 phase I-III vaccine clinical trials, ... as well as a vast array of other ...
(Date:3/30/2015)... , March 30, 2015  NuGene International, Inc. ... corporation, NuGene BioPharma, Inc. has added another internationally ... Dr. Guan is an internationally recognized researcher in ... college education at Peking University, China ... from the University of North Carolina, Chapel Hill. ...
(Date:3/30/2015)... 2015 CASI Pharmaceuticals, Inc. (Nasdaq: CASI ... and commercialization of innovative therapeutics addressing cancer and other ... commercial focus on China , announced ... has approved the Company,s application to conduct a Phase ... (OCCC) patients for its proprietary drug candidate ENMD-2076.  ...
Breaking Biology Technology:Diasome Pharmaceuticals, Inc. Announces Notice of Allowance from US PTO for Liver Targeting System for Insulin 2PMG Research announces formation of VaxCorps with two industry-leading vaccine site networks 2UCI Professor Zhibin Guan Joins NuGene Advisory Board 2UCI Professor Zhibin Guan Joins NuGene Advisory Board 3CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 2CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 3CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 4CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 5
... to Stop the Spread of Pancreatic ... ... Ph.D., executive,vice president and chairman of the Pharmaceutical Research Institute (PRI),at Albany ... National Cancer Institute, part of the National Institutes,of Health. Dr. Mousa along ...
... 2008 Earnings Conference Call Tuesday, July 29, 2008, 5:00 ... p.m. U.S. EDT, FRAZER, Pa., June 26 ... results for 5:00 p.m. EDT on Tuesday, July 29, 2008., , ... July 29, 2008 Schedule 4:10 p.m. EDT ...
... NEEDHAM, Massachusetts, June 26 ,Oridion Systems Ltd. ... developer,and manufacturer of innovative capnography monitoring solutions, ... Award from IMDA, the,association of medical specialty ... acknowledges the Company,s achievements in market development,and ...
Cached Biology Technology:Albany College of Pharmacy Researcher Receives $368,445 Grant from the National Institutes of Health 2Oridion Wins 2008 Manufacturers Partnership Award From Independent Medical Distributor's Association 2Oridion Wins 2008 Manufacturers Partnership Award From Independent Medical Distributor's Association 3Oridion Wins 2008 Manufacturers Partnership Award From Independent Medical Distributor's Association 4
(Date:3/4/2015)... 04, 2015 Research and Markets ... the "Global Biometrics Market Forecast and Opportunities, ... The market for biometric authentication systems is projected ... till 2020 The driving forces for ... needs, government projects and constant development in technology. ...
(Date:3/2/2015)... 2, 2015  Businesses have a new option ... Tharon Rankins Enterprises has announced the launch of ... way for businesses to protect their customers, personal ... Beconux is a biometric transaction processing ... similarly to an ATM machine, the new system ...
(Date:2/24/2015)... YORK , Feb. 24, 2015 This report ... The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... . Annual estimates and forecasts are provided for the ... provided for these markets. Market data and analytics are derived ...
Breaking Biology News(10 mins):Global Biometrics Market Forecast and Opportunities, 2020 2Global Biometrics Market Forecast and Opportunities, 2020 3Personal Data Protection Company Launches New Product 2World Iris Biometrics Industry 2World Iris Biometrics Industry 3World Iris Biometrics Industry 4World Iris Biometrics Industry 5World Iris Biometrics Industry 6World Iris Biometrics Industry 7World Iris Biometrics Industry 8World Iris Biometrics Industry 9World Iris Biometrics Industry 10World Iris Biometrics Industry 11
... at UT Southwestern Medical Center are among an elite group ... find biomarkers for lung cancer that develops in people who ... Research Network (EDRN) and the Canary Foundation, a nonprofit organization ... funding of $1 million each for the first year of ...
... the gene involved in regulating serotonin and norepinephrine in ... adults with developmental and intellectual disabilities, new research indicates. ... issue of the American Journal on Intellectual and ... http://tinyurl.com/mw8baj . "Problem behaviors in these populations account ...
... Plata/Leipzig. Increasing numbers of children around the world are ... attacks. Although the key external causes of these diseases ... air pollution), it had not previously been possible to ... have a targeted impact on them. Researchers at the ...
Cached Biology News:$2 million grant aids study of lung cancer in people who never smoked 2$2 million grant aids study of lung cancer in people who never smoked 3Genetic marker linked to problem behaviors in adults with developmental disabilities 2When children have breathing problems 2When children have breathing problems 3
Mouse Aminopeptidase P2/XPNPEP2 Affinity Purified PAb Protein Family: Aminopeptidases, Metalloproteases...
... 53 new primer sets added in Dec ... than 3 hours , Detection from ... , Specific primers available for hundreds ... either real-time or end-point RT-PCR , ...
AGAROSE PREP, 50G, 1 EA. Category: Genephor Precast Gels....
in vitro Translation, Accessory Products...
Biology Products: